DRUG THERAPY OF HYPOPIGMENTARY DISORDERS OF THE SKIN: A HOSPITAL-BASED STUDY

GIRISH K.; NEEPU GOWDA; JYOTHI R.; VIJAYAMATHY ARUNNAIR

doi:10.22159/ijpps.2023v15i4.47383

Authors

GIRISH K. Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bangalore
NEEPU GOWDA Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bangalore https://orcid.org/0009-0006-3701-0941
JYOTHI R. Department of Pharmacology, Kempegowda Institute of Medical Sciences, Bangalore
VIJAYAMATHY ARUNNAIR Department of Pharmacology, KMCH Institute of Health Sciences and Research, Coimbatore https://orcid.org/0000-0003-0885-3617

DOI:

https://doi.org/10.22159/ijpps.2023v15i4.47383

Keywords:

Quality of life, Topical therapy, Phototherapy

Abstract

Objective: To determine the pattern of drug use, adverse events (AEs), and quality of life (QOL) in hypopigmentary disorders of the skin.

Methods: A prospective, observational study was conducted on 48 newly diagnosed and untreated participants with hypopigmentary disorders who attended the dermatology outpatient department (OPD) of a tertiary care hospital in Bangalore, India. The pattern of drug therapy and AEs to the therapy were analyzed using descriptive statistics. The dermatology life quality index (DLQI) score for QOL was assessed before and after treatment using analysis of variance (ANOVA). The participants were monitored every 30 d for three months to study the appropriateness and changes in prescription patterns, AEs, and QOL.

Results: Male participants had a mean age of 36.69±15.58, while female participants had a mean age of 40.96±11.88. The different classes of drugs used were calcineurin inhibitors, growth factors, melanizing agents, glucocorticoids (GCs), antifungals, and anti-lepra drugs. QOL improved after treatment. The most common AEs include gastritis (16.6%) and acneiform eruption (10.41%).

Conclusion: This study has helped in determining the different patterns of drugs used in hypopigmentary disorders and their positive impact on QOL. The individualized prescribing pattern could improve the clinical and psychosocial outcome of the disease in the future.

Downloads

Download data is not yet available.

References

Patel AB, Kubba R, Kubba A. Clinicopathological correlation of acquired hypopigmentary disorders. Indian J Dermatol Venereol Leprol. 2013 May-Jun;79(3):376-82. doi: 10.4103/0378-6323.110800, PMID 23619442.

Fitzpatrick TB, Ortonne JP. Disorders of melanocytes: normal skin color and general considerations of pigmentary disorders. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick’s Dermatology, in General, medicine. 6th ed. Vol. 1. New York: McGraw-Hill companies; 2003. p. 819-79.

Hill JP, Batchelor JM. An approach to hypopigmentation. BMJ. 2017 Jan 12;356:i6534. doi: 10.1136/bmj.i6534. PMID 28082370.

Dogra S, Sarangal R. Pigmentary disorders: an insight. Pigment Int. 2014;1:5-7. Available from: https://www.pigmentinternational.com/text.asp?2014/1/1/5/135429.

Anstey AV. Disorders of skin color. In: Breathnach SM, Cox NH, Griffiths CEM, editors. Rook’s textbook of dermatology. 8th ed. Vol. 3. Oxford: Wiley-Blackwell Publishing Ltd; 2010. p. 58.1-58.59.

Kumarasinghe P, Uprety S, Sarkar R. Hypopigmentary disorders in Asian patients. Pigment Int. 2017;4:13-20. Available from: https://www.pigmentinternational.com/text.asp?2017/4/1/13/208351.

Narayanaswamy R, Ismail IS. Role of herbal medicines in vitiligo treatment–current status and future perspectives. Asian J Pharm Clin Res. 2018;11(9):19-23. doi: 10.22159/ajpcr.2018.v11i9.26830.

Belgaumkar VA, Chavan RB, Deshmukh NS, Warke NV. Impact of vitiligo on quality of life: A cross-sectional pilot study from Western India. J Skin Stem Cell. 2020;7(2):e107184. doi: 10.5812/jssc.107184.

Finlay AY. Quality of life indices. Indian J Dermatol Venereol Leprol. 2004 May-Jun;70(3):143-8. PMID 17642592.

Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology specific quality of life in vitiligo patients and its relation with various variables: A hospital-based cross-sectional study. J Clin Diagn Res. 2014 Jun;8(6):YC01-3. doi: 10.7860/JCDR/2014/8248.4508, PMID 25121050.

Reghu R, James E. Epidemiological profile and treatment pattern of vitiligo in a tertiary care hospital. Int J Pharm Pharm Sci. 2011;3(2):137-41.

Singam A, Chokhandre M, Parul G. Prescription pattern in management of vitiligo in a tertiary care center: a prospective observational study. Indo Am J Pharm Res. 2020;10(2):649-55.

Indraneel M, Govardhan M, Kiranmayi T, Reddy SPR, Surekha A, Divya Rekha O. Clinical profile, prescription patterns, and adverse drug reactions in patients with vitiligo: a prospective study. Asian J Pharm Clin Res. 2021;14(4):51-5.

Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor. J Fungi (Basel). 2015 Mar 12;1(1):13-29. doi: 10.3390/jof1010013, PMID 29376896.

Dina Y, McKesey J, Pandya AG. Disorders of hypopigmentation. J Drugs Dermatol. 2019 Mar 1;18(3):s115-6. PMID 30909355.

Madireddy S, Crane JS. Hypopigmented macules. StatPearls. 2022. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK563245.

Jha. AK, Karki S. Pigmentary disorders; vitiligo and melasma in context of South asian countries: a psychosocial-cosmetic challenge. Int J Dermatol Clin Res 2015;1(2):24-30. doi: 10.17352/2455-8605.000010.

Malathi M, Thappa DM. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol. 2013 Mar;58(2):93-100. doi: 10.4103/0019-5154.108029, PMID 23716796.

Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011 Oct;36(7):708-14. doi: 10.1111/j.1365-2230.2011.04088.x. PMID 21671990.

Navya CN, Jain GK, Jain V. Existing and novel therapies for psoriasis. Asian J Pharm Clin Res. 2018;11(12):82-7. doi: 10.22159/ajpcr.2018.v11i12.27383.

Al-shahwan M, Gacem SA, Shamseddin S, Sammour M. Vitamin D impact on human health and its relation with several diseases. Int J App Pharm. 2018;10(6):60-4. doi: 10.22159/ijap.2018v10i6.28776.

Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH. Phototherapy for vitiligo: A systematic review and meta-analysis. JAMA Dermatol. 2017 Jul 1;153(7):666-74. doi: 10.1001/jamadermatol.2017.0002, PMID 28355423.

Echekwube PO, Olasode OA, Onayemi EO. PUVA sol therapy in the management of vitiligo: outcome in a dermatology clinic in South-West Nigeria. Int J Res Dermatol. 2019;5(2):247-53. doi: 10.18203/issn.2455-4529.IntJResDermatol20191759.

Subhashini PK, Sankar K, Kambar C, Venkata Ramana V. Comparative study of efficacy and safety of active topical fragment of basic fibroblast growth factor (B FGF) 0.1% Solution V/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients. IOSR JDMS. 2015;14(6):41-7.

Pandhi D, Chhabra N. New insights in the pathogenesis of type 1 and type 2 lepra reaction. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec;79(6):739-49. doi: 10.4103/0378-6323.120719, PMID 24177605.

Arco RD, Nardi SM, Bassi TG, Paschoal A. Diagnosis and medical treatment of neuropathic pain in leprosy. Rev Lat Am Enfermagem. 2016 Aug 8;24:e2731. doi: 10.1590/1518-8345.0676.2731, PMID 27508904.

Attallah DA, Abdullah A, Abou Taleb DA. Effect of treatment on quality of life in Egyptian vitiligo patients using the. Arabic Version of Dermatology Life Quality Index. J Curr Med Res Pract. 2022;7:163-6.

DRUG THERAPY OF HYPOPIGMENTARY DISORDERS OF THE SKIN: A HOSPITAL-BASED STUDY

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section